tbuckley/cabot-search huggingface dataset:
Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol
Authors: Peitao Wu, Jee-Young Moon, Iyas Daghlas, Giulianini Franco, Bianca C. Porneala, Fariba Ahmadizar, Tom G. Richardson, Jonas L. Isaksen, Georgy Hindy, Jie Yao, Colleen M. Sitlani, Laura M. Raffield, Lisa R. Yanek, Mary F. Feitosa, Rafael R.C. Cuadrat, Qibin Qi, M. Arfan Ikram, Christina Ellervik, Ulrika Ericson, Mark O. Goodarzi, Jennifer A. Brody, Leslie Lange, Josep M. Mercader, Dhananjay Vaidya, Ping An, Matthias B. Schulze, Lluis Masana, Mohsen Ghanbari, Morten S. Olesen, Jianwen Cai, Xiuqing Guo, James S. Floyd, Susanne Jäger, Michael A. Province, Rita R. Kalyani, Bruce M. Psaty, Marju Orho-Melander, Paul M. Ridker, Jørgen K. Kanters, Andre Uitterlinden, George Davey Smith, Dipender Gill, Robert C. Kaplan, Maryam Kavousi, Sridharan Raghavan, Daniel I. Chasman, Jerome I. Rotter, James B. Meigs, Jose C. Florez, Josée Dupuis, Ching-Ti Liu, Jordi Merino
Journal: Diabetes Care (2021)

LDL cholesterol (LDLc)-lowering drugs modestly increase body weight and type 2 diabetes risk, but the extent to which the diabetogenic effect of lowering LDLc is mediated through increased BMI is unknown.We conducted summary-level univariable and multivariable Mendelian randomization (MR) analyses in 921,908 participants to investigate the effect of lowering LDLc on type 2 diabetes risk and the proportion of this effect mediated through BMI. We used data from 92,532 participants from 14 observational studies to replicate findings in individual-level MR analyses.A 1-SD decrease in genetically predicted LDLc was associated with increased type 2 diabetes odds (odds ratio [OR] 1.12 [95% CI 1.01, 1.24]) and BMI (β = 0.07 SD units [95% CI 0.02, 0.12]) in univariable MR analyses. The multivariable MR analysis showed evidence of an indirect effect of lowering LDLc on type 2 diabetes through BMI (OR 1.04 [95% CI 1.01, 1.08]) with a proportion mediated of 38% of the total effect (P = 0.03). Total and indirect effect estimates were similar across a number of sensitivity analyses. Individual-level MR analyses confirmed the indirect effect of lowering LDLc on type 2 diabetes through BMI with an estimated proportion mediated of 8% (P = 0.04).These findings suggest that the diabetogenic effect attributed to lowering LDLc is partially mediated through increased BMI. Our results could help advance understanding of adipose tissue and lipids in type 2 diabetes pathophysiology and inform strategies to reduce diabetes risk among individuals taking LDLc-lowering medications.
Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance
Authors: Musa Yilmaz, Muharrem Muftuoglu, Hagop Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Nicholas J. Short, Yesid Alvarado, Abhishek Maiti, Lucia Masarova, Guillermo Montalban-Bravo, Carissa Jurisprudencia, Allison M. Pike, Sanam Loghavi, Keyur Patel, Guilin Tang, Jairo A. Matthews, Steven M. Kornblau, Elias J. Jabbour, Guillermo Garcia-Manero, Vivian Ruvolo, Farhad Ravandi, Michael Andreeff, Naval Daver
Journal: Blood (2021)
A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma and Prior Exposure to Daratumumab, an Immunomodulatory Agent, and a Proteasome Inhibitor
Authors: Natalie Boytsov, Anissa Cyhaniuk, Gary Leung, Feng Wang, Cosmina Hogea, Matthew Lee Smith, Pallavi Mudumby
Journal: Blood (2021)
Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML
Authors: Tariq Kewan, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Hassan Awada, Suresh Kumar Balasubramanian, Bhumika J. Patel, Sudipto Mukherjee, Anjali Advani, Valeria Visconte, Hetty E. Carraway, James R. Cook, Heesun J. Rogers, Jaroslaw P. Maciejewski
Journal: Blood (2021)
Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination
Authors: Zhiwei Xiao, Huiyi Wei, Yi Xu, Ahmed Haider, Junjie Wei, Shiyu Yuan, Jian Rong, Chunyu Zhao, Guocong Li, Weibin Zhang, Huangcan Chen, Yuefeng Li, Lingling Zhang, Jiyun Sun, Shaojuan Zhang, Hai-Bin Luo, Sen Yan, Qijun Cai, Lu Hou, Chao Che, Steven H. Liang, Lu Wang
Journal: Acta Pharmaceutica Sinica B (2021)

As a member of cyclic nucleotide phosphodiesterase (PDE) enzyme family, PDE10A is in charge of the degradation of cyclic adenosine (cAMP) and guanosine monophosphates (cGMP). While PDE10A is primarily expressed in the medium spiny neurons of the striatum, it has been implicated in a variety of neurological disorders. Indeed, inhibition of PDE10A has proven to be of potential use for the treatment of central nervous system (CNS) pathologies caused by dysfunction of the basal ganglia-of which the striatum constitutes the largest component. A PDE10A-targeted positron emission tomography (PET) radioligand would enable a better assessment of the pathophysiologic role of PDE10A, as well as confirm the relationship between target occupancy and administrated dose of a given drug candidate, thus accelerating the development of effective PDE10A inhibitors. In this study, we designed and synthesized a novel 18F-aryl PDE10A PET radioligand, codenamed [18F]P10A-1910 ([18F]9), in high radiochemical yield and molar activity via spirocyclic iodonium ylide-mediated radiofluorination. [18F]9 possessed good in vitro binding affinity (IC50 = 2.1 nmol/L) and selectivity towards PDE10A. Further, [18F]9 exhibited reasonable lipophilicity (logD = 3.50) and brain permeability (Papp > 10 × 10-6 cm/s in MDCK-MDR1 cells). PET imaging studies of [18F]9 revealed high striatal uptake and excellent in vivo specificity with reversible tracer kinetics. Preclinical studies in rodents revealed an improved plasma and brain stability of [18F]9 when compared to the current reference standard for PDE10A-targeted PET, [18F]MNI659. Further, dose-response experiments with a series of escalating doses of PDE10A inhibitor 1 in rhesus monkey brains confirmed the utility of [18F]9 for evaluating target occupancy in vivo in higher species. In conclusion, our results indicated that [18F]9 is a promising PDE10A PET radioligand for clinical translation.
Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study
Authors: Andrew M. Brunner, Yiwen Liu, Lourdes M. Mendez, Jacqueline S. Garcia, Philip C. Amrein, Donna S. Neuberg, Emma Dean, Simon Smith, Richard M. Stone, Amir T. Fathi, Matthew J. Walter, Timothy A. Graubert, Meagan A. Jacoby
Journal: Blood (2021)
Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells
Authors: Frank Cichocki, Jode P Goodridge, Ryan Bjordahl, Svetlana Gaidarova, Sajid Mahmood, Ramzey Abujarour, Zachary Davis, Hongbo Wang, Katie Tuininga, Behiye Kodal, Martin Felices, Paul Rogers, Greg Bonello, Janel Huffman, Thomas Dailey, Tom Lee, Peter Szabo, Lilly Wong, Sarah Cooley, Bahram Valamehr, Jeffrey S. Miller
Journal: Blood (2021)
Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study
Authors: Michele Malagola, Nicola Polverelli, Massimo Martino, Vicky Rubini, Maria Teresa Lupo Stanghellini, Francesca Patriarca, Renato Fanin, Benedetto Bruno, Luisa Giaccone, Danilo Giuseppe Faraci, Giovanni Grillo, Stefania Bramanti, Luca Castagna, Paolo Bernasconi, Anna Amelia Colombo, Marco De Gobbi, Paolo Nicoli, Annalisa Natale, Stella Santarone, Elisabetta Terruzzi, Attilio Olivieri, Ilaria Scortechini, Patrizia Chiusolo, Elisabetta Metafuni, Angelo Michele Carella, Emanuela Merla, Marco Casini, Irene M Cavattoni, Mario Arpinati, Chiara Nozzoli, Ilaria Cutini, Patrizio Mazza, Annamaria Mazzone, Simona Bassi, Francesco Onida, Giorgia Saporiti, Filippo Antonio Canale, Adriana Vacca, Eugenia Piras, Piero Galieni, Sadia Falcioni, Mario Luppi, Giulia Debbia, Anna Paola Iori, Ursula La Rocca, Vincenzo Pavone, Anna Mele, Cristina Skert, Francesca Carobolante, Paola Carluccio, Carlo Borghero, Francesca Elice, Anna Proia, Fulvia Fanelli, Carmine Selleri, Nicoletta Sacchi, Sonia Mammoliti, Elena Oldani, Fabio Ciceri, Francesca Bonifazi, Domenico Russo
Journal: Blood (2021)
The Role of Hemoglobin and Hemolysis on Transcranial Doppler Velocities in Children with Sickle Cell Disease: Data from a Natural History Cohort
Authors: Giulia Reggiani, Beatrice Coppadoro, Vania Munaretto, Renzo Manara, Claudio Baracchini, Alessio Pieroni, Federica Viaro, Irene Agodoa, Anne Beaubrun, Alessandra Biffi, Laura Sainati, Raffaella Colombatti
Journal: Blood (2021)
Hemoglobinopathies and Cancer: Preliminary Results of an Italian Multicenter Experience
Authors: Raffaella Origa, Filomena Longo, Rosario Di Maggio, Elena Cassinerio, Valeria Maria Pinto, Antonella Quarta, Maddalena Casale, Barbara Gianesin, Susanna Barella, Andrea Piolatto, Aurelio Maggio, Giovanna Graziadei, Claudia Romano, Silverio Perrotta, Gian Luca Forni
Journal: Blood (2021)
Deep Deconvolution of the Hematopoietic Stem Cell Regulatory Microenvironment Reveals a High Degree of Specialization and Conservation between Mouse and Human
Authors: Jin Ye, Isabel A Calvo, Itziar Cenzano, Amaia Vilas-Zornoza, Xabier Martinez-de-Morentin, Miren Lasaga, Diego Alignani, Bruno Paiva, Ana C Viñado, Patxi San Martin-Uriz, Juan P Romero, Delia Quilez Agreda, Marta Miñana Barrios, Ignacio Sancho González, Gabriele Todisco, Luca Malcovati, Nuria Planell, Borja Saez, Jesper Tegner, Felipe Prosper, David Gomez Cabrero
Journal: Blood (2021)
Empirical validation of an automated approach to data use oversight
Authors: Moran N. Cabili, Jonathan Lawson, Andrea Saltzman, Greg Rushton, Pearl O’Rourke, John Wilbanks, Laura Lyman Rodriguez, Tommi Nyronen, Mélanie Courtot, Stacey Donnelly, Anthony A. Philippakis
Journal: Cell Genomics (2021)

The current paradigm for data use oversight of biomedical datasets is onerous, extending the timescale and resources needed to obtain access for secondary analyses, thus hindering scientific discovery. For a researcher to utilize a controlled-access dataset, a data access committee must review her research plans to determine whether they are consistent with the data use limitations (DULs) specified by the informed consent form. The newly created GA4GH data use ontology (DUO) holds the potential to streamline this process by making data use oversight computable. Here, we describe an open-source software platform, the Data Use Oversight System (DUOS), that connects with DUO terminology to enable automated data use oversight. We analyze dbGaP data acquired since 2006, finding an exponential increase in data access requests, which will not be sustainable with current manual oversight review. We perform an empirical evaluation of DUOS and DUO on selected datasets from the Broad Institute's data repository. We were able to structure 118/123 of the evaluated DULs (96%) and 52/52 (100%) of research proposals using DUO terminology, and we find that DUOS' automated data access adjudication in all cases agreed with the DAC manual review. This first empirical evaluation of the feasibility of automated data use oversight demonstrates comparable accuracy to human-based data access oversight in real-world data governance.
TAD-like single-cell domain structures exist on both active and inactive X chromosomes and persist under epigenetic perturbations
Authors: Yubao Cheng, Miao Liu, Mengwei Hu, Siyuan Wang
Journal: Genome biology (2021)

Abstract Background Topologically associating domains (TADs) are important building blocks of three-dimensional genome architectures. The formation of TADs has been shown to depend on cohesin in a loop-extrusion mechanism. Recently, advances in an image-based spatial genomics technique known as chromatin tracing lead to the discovery of cohesin-independent TAD-like structures, also known as single-cell domains, which are highly variant self-interacting chromatin domains with boundaries that occasionally overlap with TAD boundaries but tend to differ among single cells and among single chromosome copies. Recent computational modeling studies suggest that epigenetic interactions may underlie the formation of the single-cell domains. Results Here we use chromatin tracing to visualize in female human cells the fine-scale chromatin folding of inactive and active X chromosomes, which are known to have distinct global epigenetic landscapes and distinct population-averaged TAD profiles, with inactive X chromosomes largely devoid of TADs and cohesin. We show that both inactive and active X chromosomes possess highly variant single-cell domains across the same genomic region despite the fact that only active X chromosomes show clear TAD structures at the population level. These X chromosome single-cell domains exist in distinct cell lines. Perturbations of major epigenetic components and transcription mostly do not affect the frequency or strength of the single-cell domains. Increased chromatin compaction of inactive X chromosomes occurs at a length scale above that of the single-cell domains. Conclusions In sum, this study suggests that single-cell domains are genome architecture building blocks independent of the tested major epigenetic components.
What support do young people affected by adverse childhood experiences need?
Authors: Helen Saul, Deniz Gursul
Journal: BMJ (2021)

The study Lester S, Khatwa M, Sutcliffe K. Service needs of young people affected by adverse childhood experiences (ACEs): A systematic review of UK qualitative evidence. Child Youth Serv Rev 2020;118:105429. To read the full NIHR Alert, go to https://evidence.nihr.ac.uk/alert/support-needs-of-young-people-affected-by-adverse-childhood-experiences/
Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis
Authors: Susan L Heatley, Elyse C Page, Laura N Eadie, Barbara J McClure, Jacqueline Rehn, David T Yeung, Michael Philip Osborn, Tamas Revesz, Maria Kirby, Deborah L White
Journal: Blood (2021)
Sirpα and CSF1R Positive Tissue Macrophages Are Increased in Patients with Follicular Lymphoma Who Relapse after Frontline Lenalidomide and Rituximab
Authors: Mario L. Marques-Piubelli, Edwin R. Parra, Lei Feng, Mariana Gallardo, Luisa Solis Soto, Ignacio I. Wistuba, Christopher R. Flowers, Sattva S. Neelapu, Francisco Vega, Paolo Strati
Journal: Blood (2021)
The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
Authors: Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly Amelsberg, Sean M Devlin, Raymone Pajarillo, John B Slingerland, Silvia Beghi, Pamela S Herrera, Paul A Giardina, Annelie Clurman, Emmanuel A Dwomoh, Gabriel K Armijo, Antonio L.C. Gomes, Eric R Littmann, Jonas Schluter, Emily Fontana, Ying Taur, Jae H Park, Maria Lia Palomba, Elizabeth Halton, Josel D Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel-Angel Perales, Craig W. Freyer, Alfred L Garfall, Shannon H Gier, Sunita Nasta, Daniel J Landsburg, James N Gerson, Jakub Svoboda, Justin Cross, Elise A Chong, Sergio A Giralt, Saar Gill, Isabelle Rivière, David L Porter, Stephen J Schuster, Michel Sadelain, Noelle V Frey, Renier J Brentjens, Carl H June, Eric G Pamer, Jonathan U Peled, Marco Ruella, Marcel van den Brink, Andrea Facciabene
Journal: Blood (2021)
Abstract 9984: Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study
Authors: Khaled Shelbaya, Brian Claggett, Pranav Dorbala, Hicham Skali, Scott Solomon, Kuni Matsushita, Suma H Konety, Thomas Mosley, Amil M Shah
Journal: Circulation (2021)

Introduction: AHA/ACC guidelines endorse the conceptual framework of valvular heart disease (VHD) stages to emphasize the progressive nature of VHD. However, to our knowledge, no community-based estimates of the prevalence of VHD stages exist, particularly in late-life when VHD prevalence is highest. Methods: Among 6,118 participants in the community-based Atherosclerosis Risk in Communities (ARIC) study who underwent comprehensive echocardiography at the 5 th study visit (2011-2013), VHD stages were defined based on AHA/ACC guideline recommendations. The association of the VHD stage with the incidence of heart failure (HF), myocardial infarction (MI), stroke, atrial fibrillation (AF), and death post-Visit 5 were assessed using multivariable Cox proportional hazard models. Models were adjusted for age, sex, race, Field Center, hypertension, diabetes, prior MI, HF, body mass index, and systolic blood pressure. Results: The mean age was 76±5 years; 58% were women, 22% were Black. Stage A VHD was present in 39%, stage B in 17%, stage C/D in 1 %, and 0.7% had previously undergone valve replacement or repair. Mild mitral regurgitation was the most common single valvular lesion in Stage A (42%), while isolated mild aortic regurgitation accounted for the majority of Stage B (51%), and aortic stenosis was the most common valvular lesion in Stage C/D (80%). Over a median follow-up of 5.5 (IQR 3.7-7.7 years), Stage A, B, and C/D VHD were each associated with a heightened risk of incident HF, MI, AF, and death in multivariable models (Figure 1). VHD stages were not associated with incident stroke. Conclusion: Among older adults in the community, at-risk (Stage A, 39%) and progressive (Stage B, 17%) VHD is prevalent. Stage A and Stage B VHD are associated with a heightened risk of incident cardiovascular events independent of traditional cardiovascular risk factors. Figure1: Forest plot for adjusted HR (95% CI) associated with stage A, B, and C/D (stage 0 was the reference group)
Indoleamine 2,3-dioxygenase 1 is essential for sustaining durable antibody responses
Authors: Shivana M Lightman, Jennifer L Peresie, Louise M Carlson, G Aaron Holling, Mackenzie M Honikel, Colin A Chavel, Michael J Nemeth, Scott H Olejniczak, Kelvin P Lee
Journal: Immunity (2021)
The Non-Erythropoietic EPO Analogue (Cibinetide) Preserves Bone Mass in Mice
Authors: Zamzam Awida, Almog Bachar, Hussam Saed, Anton Gorodov, Nathalie Ben-Califa, Maria Ibrahim, Albert Kolomansky, Jennifer Ana Iden, Liad Graniewitz Visacovsky, Tamar Liron, Sahar Hiram-Bab, Michael Brines, Yankel Gabet, Drorit Neumann
Journal: Blood (2021)
Gut Microbiota Diversity and Composition Are Altered during Therapy in Pediatric Acute Lymphoblastic Leukemia Patients
Authors: Elizabeth Yang, Svetlana Rassulova, Dhwani Sahjwani, An Harmanli, Ryan Fassnacht, Lopa Mehta, Melissa Agnello, Pamela Camejo, Suchitra Hourigan
Journal: Blood (2021)
Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study
Authors: Faisal S. Malik, Angela D. Liese, Beth A. Reboussin, Katherine A. Sauder, Edward A. Frongillo, Jean M. Lawrence, Anna Bellatorre, Catherine Pihoker, Beth Loots, Dana Dabelea, Elizabeth Mayer-Davis, Elizabeth Jensen, Christine Turley, Jason A. Mendoza
Journal: Diabetes Care (2021)

To assess the prevalence of household food insecurity (HFI) and Supplemental Nutrition Assistance Program (SNAP) participation among youth and young adults (YYA) with diabetes overall and by type, and sociodemographic characteristics.
Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML
Authors: Akriti G Jain, Quinto J Gesiotto, Somedeb Ball, Lisa Nodzon, Amanda Rodriguez, Rami S. Komrokji, David A. Sallman, Eric Padron, Andrew T. Kuykendall, Onyee Chan, Jeffrey E. Lancet, Javier Pinilla Ibarz, Kendra Sweet
Journal: Blood (2021)
Patients with Obstructive Sleep Apnea on Oronasal Continuous Positive Airway Pressure Breathe Predominantly through the Nose during Natural Sleep
Authors: Jeane Lima de Andrade Xavier, Fernanda Madeiro Leite Viana Weaver, George Lago Pinheiro, Paulo Henrique Sousa Fernandes, Pedro R. Genta, Geraldo Lorenzi-Filho
Journal: American Journal of Respiratory and Critical Care Medicine (2021)

"Patients with Obstructive Sleep Apnea on Oronasal Continuous Positive Airway Pressure Breathe Predominantly through the Nose during Natural Sleep." American Journal of Respiratory and Critical Care Medicine, 205(2), pp. 250–252
Inhibiting DNA methylation alleviates cisplatin-induced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1–PI3K/AKT pathway
Authors: Yingzi He, Zhiwei Zheng, Chang Liu, Wen Li, Liping Zhao, Guohui Nie, Huawei Li
Journal: Acta Pharmaceutica Sinica B (2021)

Cisplatin-related ototoxicity is a critical side effect of chemotherapy and can lead to irreversible hearing loss. This study aimed to assess the potential effect of the DNA methyltransferase (DNMT) inhibitor RG108 on cisplatin-induced ototoxicity. Immunohistochemistry, apoptosis assay, and auditory brainstem response (ABR) were employed to determine the impacts of RG108 on cisplatin-induced injury in murine hair cells (HCs) and spiral ganglion neurons (SGNs). Rhodamine 123 and TMRM were utilized for mitochondrial membrane potential (MMP) assessment. Reactive oxygen species (ROS) amounts were evaluated by Cellrox green and Mitosox-red probes. Mitochondrial respiratory function evaluation was performed by determining oxygen consumption rates (OCRs). The results showed that RG108 can markedly reduce cisplatin induced damage in HCs and SGNs, and alleviate apoptotic rate by protecting mitochondrial function through preventing ROS accumulation. Furthermore, RG108 upregulated BCL-2 and downregulated APAF1, BAX, and BAD in HEI-OC1 cells, and triggered the PI3K/AKT pathway. Decreased expression of low-density lipoprotein receptor-related protein 1 (LRP1) and high methylation of the LRP1 promoter were observed after cisplatin treatment. RG108 treatment can increase LRP1 expression and decrease LRP1 promoter methylation. In conclusion, RG108 might represent a new potential agent for preventing hearing loss induced by cisplatin via activating the LRP1-PI3K/AKT pathway.
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group
Authors: Alpha Diallo, Marius Trøseid, Victoria Charlotte Simensen, Anaïs Boston, Jacques Demotes, Inge Christoffer Olsen, Florence Chung, José Artur Paiva, Maya Hites, Florence Ader, Jose Ramon Arribas, Andreas Baratt-Due, Øyvind Melien, Evelina Tacconelli, Thèrèse Staub, Richard Greil, Sotirios Tsiodras, Matthias Briel, Hélène Esperou, France Mentré, Joe Eustace, Juliette Saillard, Christelle Delmas, Soizic LeMestre, Marina Dumousseaux, Dominique Costagliola, John-Arne Røttingen, Yazdan Yazdanpanah
Journal: Clinical Microbiology and Infection (2021)
Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines
Authors: Melissa Mavers, Derek Hollingsworth, Chaiyaporn Boonchalermvichian, Jeffrey Liu, Jeanette Baker, Teresa Lopes Ramos, Juliane K. Lohmeyer, Po-Yu Lin, Maria Grazia Roncarolo, Robert S. Negrin
Journal: Blood (2021)
Ethical considerations for introducing RTS,S/AS01 in countries with moderate to high Plasmodium falciparum malaria transmission
Authors: Jeff D'Souza, David Nderitu
Journal: The Lancet Global Health (2021)

On Oct 6, 2021, WHO recommended the widespread use of the RTS,S/ASO1 malaria vaccine (Mosquirix; GlaxoSmithKline, Brentford, UK) among children in areas with moderate to high Plasmodium falciparum malaria transmission.1 This recommendation was made despite RTS,S showing only a 30% reduction in preventing deadly severe malaria, falling short of the WHO effectiveness threshold of 75%, and in light of promising vaccines—such as the R21/Matrix-M—under clinical development.2–4